93 related articles for article (PubMed ID: 2156319)
21. Towards minimizing immunosuppression in pediatric liver transplant recipients.
Turmelle YP; Nadler ML; Anderson CD; Doyle MB; Lowell JA; Shepherd RW
Pediatr Transplant; 2009 Aug; 13(5):553-9. PubMed ID: 19067920
[TBL] [Abstract][Full Text] [Related]
22. Rejection versus posttransplantation lymphoproliferative disorder in a renal transplant recipient.
Troxell ML; Dunlap JB; Mittalhenkle A; Ishag M; Fan G; Huang JZ; Gatter K; Byrd DM; Webster D; Houghton DC
Am J Kidney Dis; 2008 Dec; 52(6):1174-9. PubMed ID: 18706749
[No Abstract] [Full Text] [Related]
23. Neurologic complications of orthotopic liver transplantation.
Bronster DJ; Emre S; Mor E; Sheiner P; Miller CM; Schwartz ME
Mt Sinai J Med; 1994 Jan; 61(1):63-9. PubMed ID: 8183296
[TBL] [Abstract][Full Text] [Related]
24. Late onset of severe graft-versus-host disease following liver transplantation.
Sun B; Zhao C; Xia Y; Li G; Cheng F; Li J; Zhang F; Wang X
Transpl Immunol; 2006 Nov; 16(3-4):250-3. PubMed ID: 17138062
[TBL] [Abstract][Full Text] [Related]
25. [The most frequent complications in the postoperative period of hepatic transplantation at the pediatric intensive care unit].
Ruza F; Delgado MA; Dorao P; Goded F; García S
An Esp Pediatr; 1992 Jun; 36 Suppl 49():19-22. PubMed ID: 1416465
[No Abstract] [Full Text] [Related]
26. Long-term survival after post-transplant lymphoproliferative disease in children.
Nathanson S; Debray D; Delarue A; Deschênes G
Pediatr Nephrol; 2002 Aug; 17(8):668-72. PubMed ID: 12185479
[TBL] [Abstract][Full Text] [Related]
27. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression.
McAlister V; Grant D; Roy A; Yilmaz Z; Ghent C; Wall W
Transplant Proc; 1993 Feb; 25(1 Pt 2):1400-1. PubMed ID: 8442154
[No Abstract] [Full Text] [Related]
28. Diagnosis and management of allograft failure.
Burton JR; Rosen HR
Clin Liver Dis; 2006 May; 10(2):407-35, x. PubMed ID: 16971269
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder.
Bar-Natan M; Nagler A
Isr Med Assoc J; 2006 Mar; 8(3):205-7. PubMed ID: 16599060
[No Abstract] [Full Text] [Related]
30. Key features distinguishing post-transplantation lymphoproliferative disorders and acute liver rejection.
Rizkalla KS; Asfar SK; McLean CA; Garcia BM; Wall WJ; Grant DR
Mod Pathol; 1997 Jul; 10(7):708-15. PubMed ID: 9237182
[TBL] [Abstract][Full Text] [Related]
31. Post-transplantation lymphoproliferative disorder versus acute liver rejection: do we need a scoring system?
Dietze O
Adv Anat Pathol; 1998 Jan; 5(1):30-5. PubMed ID: 9868511
[No Abstract] [Full Text] [Related]
32. Postoperative clinical problems in the liver transplant patient.
Agnes S; Avolio AW; Azzaretto M; Magalini SC; Castagneto M
Rays; 1994; 19(3):304-18. PubMed ID: 7800840
[No Abstract] [Full Text] [Related]
33. Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation.
Zein NN; Perez RG; Wiesner RH
Hepatology; 2000 Mar; 31(3):808-9. PubMed ID: 10722316
[No Abstract] [Full Text] [Related]
34. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C.
McLaughlin K; Wajstaub S; Marotta P; Adams P; Grant DR; Wall WJ; Jevnikar AM; Rizkalla KS
Liver Transpl; 2000 Sep; 6(5):570-4. PubMed ID: 10980055
[TBL] [Abstract][Full Text] [Related]
35. Liver retransplantation: indications and outcomes.
Wang ZF; Liu C
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):175-8. PubMed ID: 15138104
[TBL] [Abstract][Full Text] [Related]
36. [Lymphoproliferative disorders after liver transplantation].
Pageaux GP
Gastroenterol Clin Biol; 2001 Apr; 25(4):357-66. PubMed ID: 11449124
[No Abstract] [Full Text] [Related]
37. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
38. Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.
Cornejo A; Bohnenblust M; Harris C; Abrahamian GA
Cancer Chemother Pharmacol; 2009 Sep; 64(4):857-60. PubMed ID: 19588139
[TBL] [Abstract][Full Text] [Related]
39. Hypertension and renal dysfunction in long-term liver transplant recipients.
Gonwa TA
Liver Transpl; 2001 Nov; 7(11 Suppl 1):S22-6. PubMed ID: 11689773
[TBL] [Abstract][Full Text] [Related]
40. [Complications in 52 liver transplantations excluding graft rejection].
Bresson-Hadni S; Guerzider P; Miguet JP; Becker MC; Christophe JL; Paintaud G; Mantion G; Landecy G; Gillet M
Gastroenterol Clin Biol; 1990; 14(5):474-82. PubMed ID: 2365177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
